Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 33 pages report, published by Global Markets Direct

Keywords : Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutic Products under Development, Key Players in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutics, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline Overview, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline Assessment

Report ThumbnailJune-2017
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Aryl Hydrocarbon Receptor - Pipeline Review, H1 2017'; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.

The report 'Aryl Hydrocarbon Receptor - Pipeline Review, H1 2017' outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Immunology which include indications Breast Cancer, Type 1 Diabetes (Juvenile Diabetes), Androgen-Sensitive Prostate Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Multiple Sclerosis, Obesity, Osteoporosis, Ovarian Cancer, Solid Tumor and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
- The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Hercules Pharmaceuticals BV, H1 2017
  • Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Pipeline by Shenogen Pharma Group Ltd, H1 2017
  • Dormant Projects, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Overview
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Companies Involved in Therapeutics Development
  • Hercules Pharmaceuticals BV
  • Nippon Kayaku Co Ltd
  • Shenogen Pharma Group Ltd
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Drug Profiles
  • CB-7993113 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CDR-914K058 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cinnabarinic acid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ITE - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NK-150460 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNG-162 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Products
  • Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 02, 2015: Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer
  • Sep 15, 2015: Icaritin Enters Fast Track Review for NDA
  • Sep 18, 2014: Icaritin Ph I Result Presents at 2014 CSCO
  • Jun 13, 2013: Shenogen Pharma Group: Icaritin Phase II advisory meeting held in Beijing
  • Jun 07, 2013: Icaritin Phase I data presented at 2013 ASCO Annual Meeting: June 3rd, 2013
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectAryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2017Product ThumbnailAryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2017, Industry ReportProduct #: 829035
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved